Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Nature medicine - 1 Feb 2015

Chan Steven M, Thomas Daniel, Corces-Zimmerman M Ryan, Xavy Seethu, Rastogi Suchita, Hong Wan-Jen, Zhao Feifei, Medeiros Bruno C, Tyvoll David A, Majeti Ravindra

Abstract excerpt

Mutant isocitrate dehydrogenase (IDH) 1 and 2 proteins alter the epigenetic landscape in acute myeloid leukemia (AML) cells through production of the oncometabolite (R)-2-hydroxyglutarate (2-HG). Here we performed a large-scale RNA interference (RNAi) screen to identify genes that are synthetic l...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Electron Transport
Share to Electron Transport Complex IV

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutarates

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Proto-Oncogene Proteins c-bcl-2

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 25599133
DOI: 10.1038/nm.3788
PMCID: PMC4406275

Genes

IDH1
IDH2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25599133-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.PMID 25599133Read ↗

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.Semantic proximity Read ↗

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.Semantic proximity Read ↗

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.Semantic proximity Read ↗

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.Semantic proximity Read ↗

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.Semantic proximity Read ↗

Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.Semantic proximity Read ↗

Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.Semantic proximity Read ↗

IDH2 mutations in acute myeloid leukemia.Semantic proximity Read ↗

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.